Vu, Binh T.
F. Hoffmann-La Roche AG
4 papers on CoChatORCID 0000-0001-5137-1416
Most cited papers
- Verified
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science
Cancer-related Molecular PathwaysHeat shock proteins research
Cited by 4,661
- Verified
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences
Cancer-related Molecular PathwaysHeat shock proteins research
Cited by 708
- Verified
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters
Cancer-related Molecular PathwaysHeat shock proteins research
Cited by 395
- Verified
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 283
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free